BeyondSpring (BYSI) Appoints Mark Santos to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors
November 10, 2021 7:00 AM ESTNEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the Company or BeyondSpring) (NASDAQ: BYSI), a clinical stage biopharmaceutical company focused on the development of innovative cancer therapeutics, today announced the appointment of Mark Santos, RPh, to its Board of Directors, effective immediately. Mr. Santos has over 30 years of executive experience across the healthcare and pharmaceutical industries, currently serving as the Senior Vice President of Pharma Strategy & Contracting at OneOncology. He was President of ION Solutions, the leading GPO in the U.S., from 2011 to 2018.
Were honored to have industry veteran Mr. Santos... More
